SCHEMBL15083289

SCHEMBL15083289

CN[C@@H](CC(=O)O)C(=O)N1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 2/20 0.39
MMP2 P08253 2/20 0.39
MMP8 P22894 2/20 0.39
ALDH1A1 P00352 1/20 0.38
FPR2 P25090 2/20 0.36
HTT P42858 1/20 0.36
CPB2 Q96IY4 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
HPGD P15428 2/20 0.35
TSHR P16473 2/20 0.35
GAA P10253 1/20 0.35
MMP3 P08254 1/20 0.35
RRM1 P23921 4/20 0.34
RRM2 P31350 4/20 0.34
RRM2B Q7LG56 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23157003 1.00 MMP1 (0.39) MMP1MMP2MMP8ALDH1A1FPR2
SCHEMBL24963372 0.98 MMP1 (0.36) MMP1MMP2MMP8FPR2RRM1
SCHEMBL24965299 0.98 MMP1 (0.36) MMP1MMP2MMP8FPR2RRM1
SCHEMBL24966043 0.96 REN (0.36) MMP1MMP2MMP8RRM1RRM2
SCHEMBL22008662 0.91 POLB (0.37) ALDH1A1
SCHEMBL23879197 0.83 MEN1 (0.42) MMP8ALDH1A1HTTTSHRGAA
SCHEMBL24580423 0.83 CCKBR (0.41) MMP1MMP2MMP8HTTCPB2
SCHEMBL24966123 0.83 FPR2 (0.38) MMP1MMP2MMP8FPR2HTT
SCHEMBL24965917 0.83 MEN1 (0.42) MMP8ALDH1A1HTTTSHRGAA
SCHEMBL4566691 0.81 MMP1 (0.41) MMP1MMP2MMP8ALDH1A1DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117279928-A Process for the preparation of cyclic compounds comprising N-substituted amino acid residues 中外制药株式会社 2023-12-22 CN disclosed
US-20230295221-A1 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-09-21 US disclosed
CN-116615219-A Method for producing pharmaceutical product comprising freeze-drying step using mixed solvent 中外制药株式会社 2023-08-18 CN disclosed
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-26 US disclosed
WO-2022138891-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE 中外製薬株式会社 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID DNPEP, VIP, NPEPPS MMP1 3245/4885MMP2 2333/4885MMP8 2070/4885
US-20230295221-A1 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES NGLY1, VIP, DNPEP MMP1 3436/4885MMP2 2503/4885MMP8 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.